Environmental Protection Agency EPA release draft manufacturer requested risk evaluation for DIDP and DINP under Toxic Substances Control Act for hazard assessments
Global Chemical Regulatory Updates September 2023 natlawreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from natlawreview.com Daily Mail and Mail on Sunday newspapers.
Friday, January 22, 2021
Australia
Certain NICNAS Exemption Provisions Available Until August 31, 2022: Australia announced on December 17, 2020, that under the transitional arrangements, some exemption provisions that existed under the previous law, the Industrial Chemicals (Notification and Assessment) Act 1989, will be available to introducers until
August 31, 2022. Introductions made under this arrangement are taken to be Australian Industrial Chemicals Introduction Scheme (AICIS) “reported introductions” under Section 27 of the Industrial Chemicals Act 2019 (current law). Australia states that this means that if the introduction meets the criteria for one of the exemption provisions that existed under the National Industrial Chemicals Notification and Assessment Scheme (NICNAS), companies are authorized to introduce the chemical under AICIS as a “reported introduction” until
Search jobs 18-Jan-2021 Asia Pacific Alopecia Treatment Market Revenue to Worth Over US$ 3,214.8 Million by 2027, Owing to Increasing Clinical Trials in the Treatment of Alopecia
Male or female pattern baldness, alopecia areata, telogen effluvium, and anagen effluvium are some of the types of alopecia. Topical alopecia drugs formulation are used in creams, oils, lotions, shampoos, foam forms that are intended to apply on the scalp in alopecia treatment.
Asia Pacific
US$ 4,060.9 Mn in terms of value and is expected to reach
US$ 6,427.7 Mn by the end of
2027.
Asia Pacific Alopecia Treatment
Market: Drivers
Increasing clinical trials in the treatment of alopecia is expected to propel growth of the Asia Pacific alopecia market over the forecast period. For instance, in June 2020, Concert Pharmaceuticals Inc. released new data analyses from its Phase 2 dose-ranging clinical trial of its investigational agent CTP‑543 for t